Ranitidine bismuth citrate with clarithromycin alone or with metronidazole for the eradication of Helicobacter pylori

Alimentary Pharmacology and Therapeutics

Volumn 15, Issue 8, 2001, Pages 1199-1204

  Bardhan, K D ^a   Morton, D ^a   Perry, M J ^b   Sanders, D S ^a   Morris, P ^a   Rowland, A ^b   Thompson, M ^a   Mitchell, T R ^b   Roberts, P M ^a  

^a ROTHERHAM GENERAL HOSPITAL   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; METRONIDAZOLE; RANITIDINE BISMUTH CITRATE; UREA;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM CULTURE; BACTERIUM DETECTION; BREATH ANALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ERADICATION THERAPY; FEMALE; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; PEPTIC ULCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; BISMUTH; BREATH TESTS; CARBON ISOTOPES; CLARITHROMYCIN; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DYSPEPSIA; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; PEPTIC ULCER; RANITIDINE; TREATMENT OUTCOME; UREA; UREASE;

EID: 0034913124     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2001.01040.x     Document Type: Article

References (18)

1. The European Helicobacter pylori Study Group (EHPSG). Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report
2. The report of the Digestive Health Initiative International Update Conference on Helicobacter pylori
3. Who should be treated for Helicobacter pylori infection? A review of consensus conferences and guidelines
4. Helicobacter pylori consensus. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection
5. Reply to Duggan A, Williamson R. Efficacy of ranitidine bismuth citrate (RBC) dual and triple therapies for the eradication of Helicobacter pylori
6. New concepts concerning management of Helicobacter pylori infection: 2 Years after the Maastricht Consensus Report
7. Clarithromycin dual therapy regimens for eradication of Helicobacter pylori: A review
8. Efficacy ofranitidine bismuth citrate (RBC) dual and triple therapies for the eradication of Helicobacter pylori
9. 13C-urea breath test for the detection of Helicobacter pylori
10. One week clarithromycin triple therapy regimens for eradication of Helicobacter pylori
11. Ranitidine bismuth citrate plus clarithromycin 7-day regimen is effective in eradicating Helicobacter pylori in patients with duodenal ulcer
12. Ranitidine bismuth citrate with clarithromycin given for 7 days effectively eradicates H. pylori
13. What are appropriate end-points for Helicobacter pylori eradication in the treatment of duodenal ulcer?
14. A six-year assessment of tinidazole, metronidazole, clarithromycin, tetracycline and amoxycillin resistance in Helicobacter pylori clinical isolates: A rising tide of antibiotic resistance?
15. Metronidazole resistance does not influence the efficacy of triple therapy with ranitidine bismuth citrate, clarithromycin and metronidazole for H. pylori infection
16. Ranitidine bismuth citrate can help to overcome Helicobacter pylori resistance to clarithromycin in vivo
17. Development of clarithromycin resistance is 2.7 times less likely with ranitidine bismuth citrate than with omeprazole
18. Ranitidine bismuth citrate with clarithromycin given twice daily effectively eradicates Helicobacter pylori and heals duodenal ulcers